(via NewsDirect)
Vitt said the quarter was notable for
He also highlighted the importance of the recent allowance of a fourth US patent for vidofludimus calcium, enhancing its intellectual property portfolio around MS treatments and ensuring long-term commercial exclusivity.
Vitt gave an update on the status of ongoing clinical trials, including the advanced Phase 2 CALLIPER trial for MS, with significant results expected in April next year.
Moreover, he touched on
The interview also covered upcoming milestones, focusing on executing current clinical trials and preparing for future phases.
Contact Details
+1 604-688-8158
NA-editorial@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source